moved closer to the promoter, and deletion of this region had little effect on transcriptional activation by the promoter and near upstream region in the absence of the distant enhancers. The lack of independent activation by this element, as well as its dispensability when the enhancers were moved closer to the promoter, led us to hypothesize that the primary function was to couple the distant enhancers to the promoter; we named it the promoter-linked coupling element (PCE). Several factorbinding sites are possible in the PCE region (8) , including a glucocorticoid response element (GRE) (-175 to -161). Glucocorticoid receptor (GR) binding at this site repressed AFP gene expression in some cell types (18) . However, footprint analysis revealed a distinct protected site from -153 to -166 bp. That the sequence of this site is 100% conserved among rat, mouse, and human genomes (8) indicates the importance of its function.
This study was designed to further define the PCE region and the factors that bind it in hepatocytic cells. This study indicated a novel promoter-coupling factor (PCF) with a distinctive binding site. PCF expression was found only in hepatocytic cells that express AFP.
MATERIALS AND METHODS
Cell lines. Hepatic cell lines were maintained in Williams E medium plus 5% fetal calf serum (FCS) and 2 mM glutamine, except cell line McARH8994, which was maintained in 15% FCS. HepG2, Hep3B, and HuH7 cells are human hepatoma cell lines (5, 25, 29) . McARH7777 (7777), McARH8994 (8994), Reuber H4IIEC3 (H4C3), EOCST1269 (EOC), and HTCSR (HTC) are rat hepatoma cell lines (32) . HeLa (human cervical carcinoma), W138 (human fetal lung epithelium), and COS-7 (monkey kidney fibroblasts) were cultured in Eagle's minimum essential medium with 10% FCS. THP1 monocytes) and A3M (human B lymphocytes) were cultured in RPMI 1640 medium with 10% FCS (40, 45) .
Nuclear extract preparation. Crude nuclear extracts were prepared as described previously (10, 15) ; some additional modifications are described in Results. Cultured cells or tissues (rat adult liver, fetal liver, and fetal brain) were disrupted by incubation in a hypotonic buffer (10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES; pH 7.9], 1.5 mM MgCl2, 0.5 mM spermidine, 1 Following phenol extraction, the unincorporated nucleotides were removed by using a Sephadex G-50 minicolumn. Specific activities were about 5 x 107 cpm/,ug. The binding reaction mixtures (10 ,ul) contained 0.2 to 2 ng of double-stranded oligonucleotide probe, 0.75 to 5 ,ug of poly(dI-dC) -poly(dIdC), and 1 to 10 ,ug protein in 25 mM HEPES (pH 7.9)-100 mM NaCl-9 mM MgCl2-0.25 mM EDTA-18% glycerol-5 mM DTT-0.75 mM PMSF-0.75 pug each of leupeptin, antipain, and aprotinin per ml. In some reaction mixtures, unlabeled competitor oligonucleotides were added at 100-fold molar excess. After a 20-min incubation at room temperature, the mixture was electrophoresed through a 6% polyacrylamide gel in 0.5 x Tris-borate-EDTA running buffer for 1.5 h. The dried gel was autoradiographed.
Transfection and CAT assay. Plasmids were purified by banding twice in CsCl gradients. Fifteen micrograms of plasmid was added to approximately 4 x 106 HepG2 cells seeded on 75-cm2 plates, conditions determined to be nonsaturating. Comparisons were carried out on identical plates prepared at the same time. Cells were treated with 15% glycerol 4 h after addition of the DNA-Ca3(PO4)2 precipitate and further cultured in fresh medium for 2 days. Plasmids pAFP6000, which contained the entire AFP gene transcription control region, and pPAFP900, which contained only the AFP gene promoter region, were used as controls. Chloramphenicol acetyltransferase (CAT) activity was analyzed as described previously (43) .
Plasmid construction. Two intermediate plasmids were constructed for replacement of the PCE region with oligonucleotides. Plasmid pAFP6000 was constructed by ligating a 7.9-kb SacII-EcoRV (-6.1 to +1.8 kbp) fragment from pAFP7300 to VOL. 14, 1994 6618 WEN AND LOCKER SacII-EcoRV linker sites of pBluescript II SK+. pPCAT was constructed by inserting a 2.2-kb NdeI-HindIII (-2408 to -2391 and -179 bp to +2.0 kbp) fragment derived from an AFP gene plasmid which was deleted from -2391 to -178 (42) into the EcoRV-HindIII site of pBluescript II SK+. Doublestranded oligonucleotides with a PstI site at the 5' end and an AflIl site at the 3' end were synthesized and substituted for the 40-bp PstI-AflII fragment of pPCAT. Subsequently, modified promoter regions were substituted into pAFP6000 by replacing its 1.1-kb PstI-BspEI (-890 to +252 bp) fragment with the equivalent 0.4-kb fragments from the oligonucleotide-modified pPCAT plasmids. In these PCE-substituted plasmids, the most proximal enhancer was placed at -1.6 kb, compared with its location at -2.3 kbp in the intact gene region of pAFP6000. All PCE modifications were confirmed by sequencing.
Purification of PCF. Column buffers contained 25 mM HEPES (pH 7.9), 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.5 mM PMSF, 0.05% Nonidet P-40, and variable NaCl concentrations.
Twenty micrograms of HepG2 nuclear extract protein was diluted to a NaCl concentration of 50 mM and passed through a 1-ml heparin-Sepharose column (Pharmacia, Piscataway, N.J.) at 10 ml/h. The column was then washed with 20 ml of 50 mM NaCl buffer and eluted with 1 ml each of 100 mM steps. The PCF-rich fractions identified by gel shift assay were pooled, diluted to 100 mM NaCl, and concentrated to 1 ml in a Centricon-30 microfiltration cell (Amicon, Beverly, Mass.) before DNA affinity column purification.
A DNA-Sepharose column was prepared by coupling 12.5 ,ug of concatenated S2 oligonucleotide (see below) to 0.25 ml of swollen cyanogen bromide-activated Sepharose 4B (Pharmacia) according to the manufacturer's protocol, but with an overnight coupling reaction (6) .
Heparin-Sepharose column-purified PCF was mixed with 500 ,ug of poly(dI-dC) * poly(dI-dC) at 4°C for 30 min and subsequently with 0.25 ml of DNA-Sepharose resin overnight.
The mixture was loaded into a 5-ml column tube, and the passed liquid portion was passed through the same column twice at 5 ml/h. The column was washed with 2.5 ml of 300 mM buffer and eluted with 0.5-ml steps from 400 mM. The PCFrich fractions were identified by gel shift assays. The purification was monitored by running fractions through a 10% noncontinuous reducing sodium dodecyl sulfate (SDS)-polyacrylamide gel stained with Coomassie blue.
UV cross-linking. The procedure was carried out as described previously (11) , with slight modification. A probe was prepared by annealing a 12-bp primer (5'-CTGAAGTGGT CT) to the bottom strand of the P oligonucleotide and filling in 22 bases as described above in the presence of 37.5 ,uM each dATP and 5-bromo-2'-dUTP, 6 enhancers. The activity was found in a promoter deleted to -178 but not to -155. In addition, a footprint was identified from -166 to -153 bp.
To further characterize PCE binding activity, including both its binding factor and the binding site, nuclear extract from HepG2 cells was used to gel shift oligonucleotide P, which contained the AFP promoter region from -179 to -150 bp. Gel retardation with HepG2 nuclear extract showed two major bands (Fig. 1A) . The upper band increased exponentially, while the lower band increased linearly, with increasing nuclear extract protein. This result suggests that the top band represents cooperative binding while the lower band represents simple stoichiometric binding.
To determine specificity, increasing amounts of poly(dIdC) * poly(dI-dC) were added to the binding reaction mixtures as a nonspecific competitor. Alternatively, unlabeled oligonucleotide P was added as a specific competitor (Fig. 1B) . Comparison of lanes d and e shows that only the lower band was competed for by a 100-fold molar excess of the unlabeled oligonucleotide P. In contrast, the lower band was retained even when a 20,000-fold molar excess of poly(dI-dC) * poly(dIdC) was present in the binding reaction, while the top band was significantly diminished (lanes a to d). For further experiments, 5 ,ug of poly(dI-dC) -poly(dI-dC) per reaction was used to reduce the upper band.
To identify the factor that binds oligonucleotide P, a computer search of known transcription factor binding sites (27) localized five potential binding sites, GRE, NFKB, HNF3, HNF4, and HNF5, with significant similarity to the -179 to -150 region ( Fig. 2A) . In addition, an AP1 site was suggested by the studies of Bacus et al. (1) . The GRE has been previously characterized by Guertin et al. (18) .
DNA oligonucleotides (Table 1) representing each of the six potential binding sites were used as competitors, but none showed appreciable competition for binding activity ( Table 1 . Competitors were added at a 100-fold molar excess. (C) Additional competition experiments. HNF1, C/EBP, LFA1, LTFE, HBLF, and ALBD are sites for hepatocyte-enriched transcription factors; SP1, CF1, and serum response factor (SRF) are candidate sites present in the rat AFP complex 3 enhancer (17a); AFP-178 is the rat AFP promoter segment from -178 to + 1; AFP-155 is the AFP promoter segment from -155 to + 1; ALB-175 is a segment from -175 to + 14 from the rat albumin gene; and AFP-C3 is the AFP complex 3 enhancer from -6119 to -5900. All (-175 to + 14) , and the AFP gene complex 3 enhancer (-6119 to -5900) was also analyzed. Except for the AFP promoter segments, none of these additional binding sites could compete for binding to oligonucleotide P. Interestingly, competition with the 179-bp promoter segment resulted in trapping of the labeled oligonucleotide near the top of the gel. This might indicate formation of a complex containing oligonucleotide P and the promoter, a possibility that must be evaluated with further studies.
We then tested whether the six factors bound oligonucleotide P with low affinity. Oligonucleotides containing each of the sites were labeled and shifted with HepG2 nuclear extract. For each, the uncompeted gel shift was compared with selfcompetition or oligonucleotide P competition (Fig. 2D) . The results suggest that oligonucleotide P binds GR; moreover, much stronger GR binding with appropriate competition was observed with HeLa cell nuclear extract (data not shown). There also appeared to be weak AP1 binding, but limited to the lower band, which may represent c-Jun homodimers (19 indicated specific binding to oligonucleotide P by unidentified factor(s) moderately abundant in HepG2. Further experiments are required to identify these factor(s) and their binding sites within oligonucleotide P. In the absence of competition by known binding sites, we concluded that the strong specific binding to oligonucleotide P represents a novel factor, now designated PCF.
Characterization of the PCF binding site. To map the minimal PCF binding site, a series of shorter oligonucleotides were synthesized and used in competition with oligonucleotide P (Fig. 3) . In addition, those oligonucleotides that showed competition were labeled and used in gel shifts. The experiments localized the PCF binding site to a 12-base sequence, 5'-TGTCCTTGAACA-3' (oligonucleotide S2). This 12-bp sequence corresponds to the footprint (42) . Moreover, this newly identified PCF binding site is distinct from the six potential binding sites described above (Fig. 2A) . Overlapping sites like the GRE could potentially regulate PCF binding, but such activity is not evident in HepG2 extracts. TGTCCTTGAACA represents a unique binding site not found in an extensive database of transcription factor binding sites (27) .
The 12-bp PCF binding site is an incomplete inverted repeat. The 5'-half site, TGTCCT, overlaps the known GRE and includes the 3' half of GRE consensus sequence TGTYCT. Using this analysis as a basis, we designed five mutated PCE oligonucleotides, ml to m5 (Fig. 4) , in which various features were modified. Two mutations specifically targeted the 5' half. ml had two altered bases, and m2 had one; both reduced binding activity. A point mutation of T to A at position 7 in m3, designed to improve the symmetry of the inverted repeat, also reduced binding. The four altered bases of m4 totally blocked binding. Finally, m5 tested an A-to-T mutation of base 12. This neutral mutation had been previously introduced into some of FIG. 4. Competition by mutated PCF binding sites. PCE and mutated oligonucleotides are listed at the top. Mutated bases are in outline type. Oligonucleotide P was labeled and incubated with HepG2 nuclear extract in the absence or presence of a 100-fold excess of oligonucleotide P, S2, ml, m2, m3, m4, or m5 as competitor. The levels of competition were calculated from densitometric analysis of the autoradiogram.
our plasmid constructs to facilitate cloning by generating an AflII restriction site (42) , and the new analysis demonstrated that this was indeed the functional equivalent of the wild-type PCE.
Competition with the mutated oligonucleotides demonstrated three points: (i) the 5'-half mutations ml and m2 both had detrimental effects; (ii) the improved dyad symmetry of m3 was also detrimental; and (iii) mutation m4 demonstrated that the 5'-half site could not function by itself.
Effects of PCE mutation on AFP gene expression. Deletion in the PCE region greatly reduced AFP gene expression (42) . CAT gene plasmids were constructed to test whether PCF binding alone was responsible for this effect. In these plasmids, the region was shortened to the minimal 12-bp PCE or further mutated. This eliminated all elements in the region upstream of -167, including the 5' half of the GRE. These plasmids were transfected into HepG2 and compared with our standard AFP gene expression plasmids (Fig. 5) .
The minimal 12-bp PCE (pPCEwt) had 80% of the activity of the control plasmid pAFP6000, close to the activity of the full-length PCE. The minor mutation (pPCEml) moderately reduced activity. Further mutation (pPCEm2) diminished the activity to 20% of pAFP6000 activity. This was almost precisely the level of activity of plasmids with deletions to -155 (42 5 . Role of the minimal and mutated PCE in AFP gene expression. Plasmids pAFP6000, which contained the entire AFP gene transcription control region, and pPAFP900, which contained only the AFP gene promoter region, were used as controls. Activity is expressed relative to that of pAFP6000, defined as 100%. In plasmid pPCEwt, the 12-bp segment TGTCCTGAACt was substituted for the region from -890 to -155. We used the sequence in oligonucleotide mS, in which a T was substituted for the normal A of position 12 , in order to use the AflII restriction site in this region. This cloning placed the intact 12-base PCE into its normal position relative to the transcription start site but moved the enhancers 735 bases closer than in the normal gene. However, we previously determined that the PCE is required for transcription stimulation by the enhancers at this distance (42) . Plasmid pPCEml contained TtTCaTTGAACt in the same position, altered at bases 2 and 4, while plasmid pPCEm2 contained TtTCaTatAcCt, altered at bases 2, 5, 7, 8, and 10 . These constructs were all transfected by using matched HepG2 cell plates as described previously (43) , and CAT activity was determined. Relative CAT activity is CAT activity per mole of transfected DNA, normalized to the value for pAFP6000 (100%). The data are averages and standard deviations of two determinations from one transfection experiment.
Hep3B, HuH7, 7777, and 8994), AFP-negative hepatic cell lines (H4C3, EOC, and HTC), rat adult liver, and nonhepatic cell lines (HeLa, COS, Tun, W138, and A3M) were compared (Fig. 6) . A full-length PCE probe (oligonucleotide P) was used to reveal all possible specific binding in the region, while the minimal binding site, S2, was used to demonstrate PCF binding selectively. To control for the quality of the nuclear extracts, the levels of AP1, a ubiquitous factor, and HNF3, a hepatocyte-enriched factor, were monitored. These two factors were chosen for an additional reason: they were among the six potential PCE-binding factors.
The levels and distribution of the control factors AP1 and HNF3 clearly indicated that all 14 nuclear extracts contained abundant active transcription factors. AP1 was abundant in all cell lines but expressed in much lower levels in normal liver, while HNF3 was abundant in differentiated hepatocytic cells (HepG2, Hep3B, HuH7, 7777, 8994, H4C3, and liver) but deficient in dedifferentiated hepatic cell lines (EOC and HTC) and nonhepatic cells (HeLa, COS, Tun, W138, and A3M). The latter showed low levels of other factors that bound the HNF3 probe, but these were not further characterized. (Fig. 7) . Control gel retardation experiments with AP1 and C/EBP oligonucleotides were used to demonstrate functional transcription factors in these extracts and that gel retardation analysis was successful at high protein concentrations (not illustrated). At these protein concentrations, fetal liver and brain showed very strong and adult liver weak AP1 band shifts; adult liver showed strong and fetal liver weak C/EBP shifts. Dilution reduced the intensity of all control band shifts. On the basis of relative cell numbers, the PCF level in the fetal liver was 130-fold less than in the HepG2 preparation. This level could reflect low abundance, lability, or poor recovery under the conditions used for extraction. Comparable adult liver and fetal brain nuclear extracts did not show a PCF band shift.
These data strongly indicate that PCF is a novel factor associated with AFP gene expression and demonstrate several important points. First, HepG2 cells had the highest level of PCF, providing a good source for factor purification (see below). Second, PCF was detected in fetal but not adult liver. Third, there were two specific PCF bands in Hep3B and HuH7 cells, the lower of which comigrated with the band of HepG2 FIG. 7 . PCF analysis in tissue nuclear extracts. Retardation of oligonucleotide S2 was carried out as for Fig. 6 except that the oligonucleotide was labeled to 3 x 108 dpml,ug, in the presence or absence of a 100-fold excess of unlabeled competitor. Extracts were prepared with several modifications: hypotonic homogenization buffer contained 1% nonfat dry milk (35) , and all solutions contained 1 mM NaMoO4 (3) and 10 mM NaH2PO4. Highly concentrated preparations were produced from about 1 g of tissue by extracting nuclei with 3 volumes of hypertonic buffer and dialyzing against buffer containing 150 mM NaCl. The illustrated gel shifts used the following levels of protein: HepG2, 2.6 jig; adult liver (Ad. Liv.), 70 jig; fetal liver (F. Liv.), 21 ,ug; and fetal brain (F. Br.), 17 jig. cells. Whether these represent two distinct factors or different forms of the same factor will require further investigation. Finally, the cell type distribution of PCF is totally unlike that of AP1, HNF3, HNF4, HNF5, NFKB, or GR ( Fig. 6 and additional data not shown), indicating that PCF is distinct from all of these potential PCE-binding factors.
Partial purification of PCF. To further characterize PCF, we carried out small-scale purification using heparin-Sepharose chromatography followed by DNA-binding-site affinity chromatography. Because of its abundance of PCF, HepG2 nuclear extract was chosen as the source. Gel shift of the full PCE region (oligonucleotide P) was used to monitor purification, since this probe showed the removal of other specific and nonspecific binding proteins. Conversely, the minimum binding site oligonucleotide S2 was concatenated to prepare the DNA-binding-site affinity column.
Heparin-Sepharose chromatography effectively enriched PCF, which eluted at 0.5 to 0.6 M NaCl (Fig. 8A) . A typical purification gave 10-to 20-fold enrichment. The pooled 0.5 to 0.6 M fractions were further purified by DNA affinity chromatography (Fig. 8B) . The activity eluted at 0.5 to 0.6 M NaCl. After purification, only the PCF-specific band shift was demonstrated, even under relatively nonspecific conditions, indicating a high degree of purification.
SDS-PAGE of the affinity column-purified fractions demonstrated three bands that copurified with gel shift activity (Fig.  8C) . These bands ranged from 32 to 34 kDa and were designated a1, a2, and ,B. Comparison of Coomassie blue-and silver-stained gels (not illustrated) demonstrated that these were not the same as bands of similar migration prominent in unfractionated nuclear protein extract. Together, the three bands represented 70 to 80% of the total protein in the 0.5 M eluate fraction. They could represent a family of factors, variant forms, or subunits of a complex. If these possibilities are correct, the purification was to near homogeneity.
To corroborate that PCF was an activity of the main peptide bands in this purification, UV cross-linking to labeled oligonucleotides was carried out (Fig. 9) . The main labeled product Oligonucleotide P also competed for binding of factors detected with HNF4 and HNF5 oligonucleotides; however, these were not the characteristic band shifts of these factors but rather bands that moved farther into the gel. These bands presumably represent uncharacterized factors that bind these oligonucleotides.
Further study of the interaction between PCF and GR should provide definitive information on the mechanism of GR-mediated repression of AFP gene expression. Analogous mechanisms involving other factors that compete for binding might explain other repressions, including developmental silencing. Our data (Fig. 2D and 6 (3) showed that mutation at the PCE greatly reduced transfected AFP gene expression. Moreover, they showed an adult liver factor, FIF, which bound to approximately the same segment we defined. The limited characterization of FTF does not allow comparison with PCF, but we did not observe a significant PCF band shift in adult liver extracts at any protein concentration.
Association of PCF with AFP gene expression. PCF was present in AFP-expressing cell lines but deficient or absent in both AFP-negative cell lines and adult liver, suggesting a direct role for PCF in AFP gene expression. PCF is thus the first transcription factor to show an association with AFP expression distinct from other markers of hepatocyte differentiation. We hypothesize that PCF plays a critical role in maintaining the high level of AFP gene expression of fetal liver and that the absence of PCF in adult liver contributes significantly, though perhaps not entirely, to postnatal silencing. The potential competition for PCF binding by other transcription factors with binding sites in the PCE region provides alternative mechanisms for AFP gene silencing. Continuing postnatal albumin gene expression may reflect the absence of a PCF binding site near the albumin promoter. The albumin promoter may couple to distant enhancers through other trans factors and cis elements that have functions similar to that of PCF (23) .
Mechanisms of promoter-enhancer coupling through PCF. The mechanisms by which PCF couples the promoter with enhancers must still be investigated. However, the gel shift experiments using gene segments as competitors (Fig. 2C ) indicate some features of these interactions. In oligonucleotide P gel shifts using unfractionated nuclear proteins and an AFP gene promoter segment (-178 to +1) as a competitor, the PCF band was replaced by a complex that barely entered the gel. Similar supershifting was not observed in simple competition with oligonucleotides, indicating the involvement of multiple factors and binding sites to form this higher complex. This result suggests that PCF binds to itself and to heterologous factors associated with the AFP promoter. PCF may also couple enhancers with the promoter by a combination of self and heterologous factor binding, but we found no evidence of direct binding of PCF to the complex 3 enhancer. Since PCE supershifting was not observed with complex 3, this single negative experiment indicates that more detailed analysis must be carried out. Such analysis should also be extended to interactions with the complex 1 and complex 2 enhancers.
The PCE may not be the only PCF-binding element in the promoter region, since the -155 to + 1 AFP promoter segment weakly competed for PCF binding activity. This observation is consistent with functional analysis (Fig. 5 and reference 42) which showed that an AFP promoter with a deleted or mutated PCE is still stimulated by distant enhancers, but at 30% of the level observed when the PCE is present. Other weaker promoter-linked coupling elements are possible, although sequence analysis did not indicate an obvious second PCF binding site.
In conclusion, PCF exerts its critical role in high-level AFP gene expression from a distal promoter region site, apparently through interactions with other sites and factors. Further analysis of PCF and its complex interactions will provide important new information not only about AFP gene regulation but also about the general mechanisms by which promoters are stimulated by distant elements.
